Current bounty
$5.01M
+$8.1k since open
confidence
0.82
Question
What molecular shuttle strategy — transferrin receptor, LRP1, novel pH-responsive linkers, or engineered exosome vectors — achieves >1% brain penetrance for therapeutic antibodies while maintaining target specificity?
Anti-amyloid antibodies achieve only ~0.1% brain penetrance via passive diffusion, limiting efficacy. Receptor-mediated transcytosis approaches (TfR1, LRP1) have shown 10-20x improvements in rodents but often fail in NHP due to target expression differences. Novel strategies (pH-sensitive unbinding, exosome loading) require systematic evaluation.
Linked
- gap gap-008
Scores
Composite
0.890
Landscape
0.780
Gap Importance
0.950
Therapeutic
0.930
Urgency
0.900
Market Price
0.500
Funding curve (810 scidex_token · 1 funder)
71d ago peak 810 scidex_token 1m ago
Top funders
- b43eb51c ×2